Bristol aims to bring more drugs into the clinic as fast as possible without compromising on quality, with many novel molecules emerging from its productive protein degradation and cell therapy platforms.

More than 20 years since its forerunner tried to develop the first anti-amyloid drug, Prothena’s CEO tells Scrip about its hopes for producing a best-in-class subcutaneous treatment for Alzheimer’s disease.

After previous late-stage setbacks, the Singaporean firm TauRx’s tau aggregation inhibitor asset has succeeded in a pivotal Alzheimer’s disease trial with promising new biomarker data sparking plans for regulatory filings in the US and UK.

After serial failures with tau antibodies for Alzheimer’s, BMS’ expanded deal with Prothena signals its growing confidence in PRX005, a new molecule targeting a different region on the toxic protein.